Cloud-based solution accelerates and simplifies managing regulated promotional and non-promotional content for life sciences organizations
ePromo addresses the challenge of increasing demand from healthcare professionals and other stakeholders for more and faster information and collateral from life sciences companies. These demands can strain existing internal compliance processes for content approval and dissemination, increasing both risk and production costs. ePromo includes workflow management of approval processes, role-based dashboards, reporting capabilities and digital asset curation, among many other features. It provides users with actionable insights into their tasks and responsibilities, exposing process bottlenecks, decreasing the time, cost and effort for creating, approving and disseminating materials globally.
“We developed ePromo as part of IQVIA’s integrated commercial technology suite, which is designed to help our customers transform to an orchestrated model as they engage customers.” said Rosenberg. “It offers a superior alternative to other commercial content management products, providing a more compelling end user experience through an advanced dashboard, streamlined processes, and meaningful reporting that drives enhanced understanding as to what’s working and what’s not.”
ePromo was specifically designed for Orchestrated Customer Engagement (OCE), IQVIA’S commercial technology solution and leverages the Company’s “platform of platforms” strategy of building products on best-in-class platforms and differentiated technology capabilities to address the unique needs of life sciences companies. IQVIA Content Management platform offerings now include solutions across clinical, regulatory and commercial, transforming the vision of “molecule to market” into a reality.
For additional information on ePromo, please visit www.iqvia.com/epromo.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps their customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
Click here to subscribe to Mobile Alerts for IQVIA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180604006513/en/
Contacts
IQVIA
Media Relations:
Tor Constantino, +1-484-567-6732
tor.constantino@iqvia.com
or
Investor Relations:
Andrew Markwick, +1-973-257-7144
andrew.markwick@iqvia.com
Source: IQVIA